Invitrogen Announces Realignment to Move Closer to Customers; John 'Kip' Miller Signs on to Lead One of Several New Focus Areas

Invitrogen Corporation (Nasdaq:IVGN), a provider ofessential life science technologies for disease research and drugdiscovery, today announced a realignment designed to drive growth bycreating an even stronger linkage between its product developmentcycle and customer base. Effective January 1, 2006, the company willcreate three new divisions under the traditional BioDiscovery andBioProduction business segments: Life Sciences, Bio-Production Systemsand Services, and Enabling Technologies. Each of the divisions willhave dedicated manufacturing, research and development, and marketingfunctions.

The Life Sciences division will focus on key molecular biology andbiomedical applications including cloning and protein expression,protein analysis, gene expression profiling, drug discovery solutionsand other molecular biology essentials. The Senior Vice President ofthis division will be Jon Hindar, most recently the CEO of DynalCorporation, which Invitrogen acquired in early 2005.

Bio-Production Systems and Services will include the current Gibcoand BioReliance products and services, as well as the company'scustomer-focused bioproduction process development initiative. NicolasBarthelemy, currently the head of global operations for Invitrogen,will lead this division.

Finally, Enabling Technologies will focus on nanotechnology,imaging and microscopy, cell separation and analysis, labeling anddetection, bead based separations, the company's antibody center ofexcellence, and will feature prominent industry brands MolecularProbes, Dynal, BioSource and Quantum Dot. Both the EnablingTechnologies and Life Sciences divisions fall under the BioDiscoverybusiness segment. Joining the company as Senior Vice President for theEnabling Technologies Division is industry veteran John L. "Kip"Miller. Miller brings to Invitrogen a successful track record of lifescience leadership highlighted by product development, sales,marketing and finance assignments. He comes to Invitrogen from BDBiosciences, where he served as Vice President and General Manager,Americas, and where he earlier led the BD Pharmingen unit. Millerholds a bachelors degree in Engineering from Michigan StateUniversity.

"At Invitrogen, we aim to create an operating system where wecompete on both technology breadth and depth," said Gregory T. Lucier,Chairman and CEO of Invitrogen Corporation. "This realignment allowsus to focus our development and commercial efforts along keytechnology workflows in order to help researchers shape the protocolsof tomorrow's medical breakthroughs."

In order to drive greater customer intimacy, the divisions willalso be tightly integrated with new technology sales specialist teams(TSS) that provide deep scientific expertise in targeted areas ofresearch. These teams will be able to draw upon solutions from acrossInvitrogen's product portfolio to address complex applications andworkflows.

"As we continue to expand our technological boundaries, it isvital that we remain closely aligned with our customers' uniquechallenges," concluded Ben Bulkley, Invitrogen's Senior Vice Presidentof Global Commercial Operations. "By creating a unified commercialunit that includes highly technical specialist teams and maximizes ourbreadth of offering, we offer a total solution for obtaining theproducts, services and support our customers need."

In addition to the structural realignment, Daryl Faulkner, SeniorVice President of Global Business Segments will retire during thefirst quarter of 2006 after seven years with the organization. Underhis leadership, Invitrogen has experienced tremendous growth andamassed a vast collection of leading technologies.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products andservices that support academic and government research institutionsand pharmaceutical and biotech companies worldwide in their efforts toimprove the human condition. The company provides essential lifescience technologies for disease research, drug discovery, andcommercial bioproduction. Invitrogen's own research and developmentefforts are focused on breakthrough innovation in all major areas ofbiological discovery including functional genomics, proteomics,bioinformatics and cell biology -- placing Invitrogen's products innearly every major laboratory in the world. Founded in 1987,Invitrogen is headquartered in Carlsbad, California, and conductsbusiness in more than 70 countries around the world. The companyglobally employs approximately 4,800 scientists and otherprofessionals and had revenues of more than $1 billion in 2004. Formore information, visit www.invitrogen.com

Safe Harbor Statement

Certain statements contained in this press release are considered"forward-looking statements" within the meaning of the PrivateSecurities Litigation Reform Act of 1995, and it is Invitrogen'sintent that such statements be protected by the safe harbor createdthereby. Forward-looking statements include, but are not limited to:1) Invitrogen will create three new divisions under the traditionalBioDiscovery and BioProduction business segments; 2) Each of thedivisions will have dedicated manufacturing, research and development,and marketing functions; 3) The Life Sciences division will focus onmolecular biology and biomedical applications, Bio-Production Systemsand Services will include the current Gibco and BioReliance productsand services and Enabling Technologies will focus on nanotechnology;imaging and microscopy, cell separation, labeling and detection, beadbased separations, and the company's antibody center of excellence; 4)Jon Hindar will lead the Life Sciences Division, Nicolas Barthelemythe Bio-Production Systems and Services Division and John L. "Kip"Miller the Enabling Technologies Division; 5) The integration willenable researchers to shape the protocols of medical breakthroughs; 6)The new divisions will be tightly integrated with the technical salesspecialist teams; and 7) Daryl Faulkner will retire in the firstquarter of 2006. Potential risks and uncertainties include, but arenot limited to, the risks: a) The details of Invitrogen's realignmentare subject to changes in structure and name; b) The details of theindividual divisions may add or replace certain functions; c) Thefocus of the new divisions is subject to changes in company strategyor market variances; d) Leadership of the new divisions is subject tochange; e) Results from the realignment may differ by customer andapplication; f) The new divisions link to the sales structure issubject to changes in company strategy; g) The timing of DarylFaulkner's retirement may vary from the stated range, as well as otherrisks and uncertainties detailed from time to time in Invitrogen'sSecurities and Exchange Commission filings.